<DOC>
	<DOCNO>NCT02434354</DOCNO>
	<brief_summary>The main purpose trial evaluate safety , tolerability adverse event profile pembrolizumab subject high risk melanoma standard care surgical resection , collect tumor tissue subject receipt pembrolizumab look experimental drug interacts tumor tissue . Subjects receive 1 dose neoadjuvant pembrolizumab , follow complete resection year adjuvant pembrolizumab</brief_summary>
	<brief_title>A Tissue Collection Study Pembrolizumab ( MK-3475 ) Subjects With Resectable Advanced Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>1 . The subject must clinical stage III resectable stage IV MEL . Subject 's may diagnosis uveal mucosal melanoma . 2 . The subject must expect adequate amount tumor burden yield 24 preoperative research core biopsy ( 14gauge needle ) specimens equivalent amount tissue ( 46 mm punch biopsy ) , addition , tissue require diagnostic purpose . 3 . The subject must expect adequate amount residual tumor preoperative research tumor tissue collection , operative research tumor collection also yield least 46 research core biopsy specimens equivalent amount tissue 4 . The subject must willing undergo two paired tumor tissue biopsy procedure obtain sample biomarker analysis . Tissue obtain must previously irradiate . 5 . Either subject subject 's legal representative must willing able provide write informed consent trial . 6 . The subject must ≥ 18 year age day sign informed consent . 7 . The subject must performance status 0 1 ECOG Performance Scale . 8 . The subject must demonstrate adequate organ function define Table 1 , screen lab must perform within 10 day treatment initiation . Table 1 Adequate Organ Function Laboratory Values System Laboratory Value Hematological Absolute neutrophil count ( ANC ) 1500/mcL Platelets 100,000/ mcL Hemoglobin 9 g/dL ≥5.6 mmol/L Renal Serum creatinine OR Measured calculateda creatinine clearance ( GFR also use place creatinine CrCl ) ≤1.5 X upper limit normal ( ULN ) OR 50 mL/min subject creatinine level &gt; 1.5 X institutional ULN UPCC # 01615 : Tissue Collection Study Pembrolizumab Advanced Melanoma Version Date : 12/30/2014 Page 10 Hepatic Serum total bilirubin 1.5 X ULN OR Direct bilirubin ≤ ULN subject total bilirubin level &gt; 1.5 ULN AST ( SGOT ) ALT ( SGPT ) 2.5 X ULN OR 5 X ULN subject liver metastasis Coagulation International Normalized Ratio ( INR ) Prothrombin Time ( PT ) Activated Partial Thromboplastin Time ( aPTT ) 1.5 X ULN unless subject receive anticoagulant therapy long PT PTT within therapeutic range intend use anticoagulant 1.5 X ULN unless subject receive anticoagulant therapy long PT PTT within therapeutic range intend use anticoagulant aCreatinine clearance calculate per institutional standard . 9 . Female subject 's childbearing potential must negative serum pregnancy test within 72 hour prior receive first dose study medication . 10 . The subject must willing use protocol define method ( ) contraception : Female subject childbearing potential must willing use 2 method contraception , abstain heterosexual sexual intercourse two week time first dose study medication , study , 120 day last dose study medication . Female subject 's childbearing potential defined woman surgically sterilize free menses &gt; 1 year . Male subject must agree use adequate method contraception start first dose study medication , study , 120 day last dose study medication . Acceptable form birth control include condom , diaphragm , cervical cap , intrauterine device ( IUD ) , surgical sterility ( tubal ligation partner undergone vasectomy ) , oral contraceptive , OR subject must agree completely abstain heterosexual intercourse . Abstinence certain time cycle , day ovulation , ovulation withdrawal acceptable method birth control 1 . Subject unresectable disease ; i.e . opinion surgical oncologist , subject 's melanoma completely remove clear margin . 2 . Subject currently participate participate study investigational agent use investigational device within 4 week first dose study treatment . 3 . Subject know hypersensitivity pembrolizumab ingredient . 4 . Subject diagnosis immunodeficiency receive systemic steroid therapy form immunosuppressive therapy within 7 day prior enrollment . 5 . Subject prior monoclonal antibody within 4 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due agent administer 4 week earlier . 6 . Subject receive prior therapy antiPD1 , antiPDL1 , antiPDL2 , antiCD137 , antiCytotoxic Tlymphocyteassociated antigen4 ( CTLA4 ) agent ( include ipilimumab ) , interferon , high dose IL1 antibody drug specifically target Tcell costimulation checkpoint pathway . 7 . Subject prior chemotherapy , target small molecule therapy , 2 week prior study Day 1 recover ( i.e. , ≤ Grade 1 baseline ) adverse event due previously administer agent Note : Subjects ≤ Grade 2 neuropathy exception criterion 8 . For subject 's received major surgery , subject must recover adequately toxicity and/or complication intervention prior start study therapy . 9 . Subject radiation therapy tumor select research collection , radiation therapy site within 4 week prior study Day 1 . 10 . Subject receive transfusion blood product ( include platelet red blood cell ) administration colony stimulate factor ( include GCSF , GMCSF recombinant erythropoietin ) within 4 week prior study Day 1 . 11 . Subject know additional malignancy progress require active treatment . 12 . Subject know active central nervous system ( CNS ) metastases and/or carcinomatous meningitis . Note : Subjects previously treat brain metastasis eligible participate provide stable ( without evidence progression image least four week prior first dose trial treatment neurologic symptom return baseline ) , evidence new enlarge brain metastasis , use steroid least 7 day prior trial treatment . 13 . Subject active autoimmune disease require systemic treatment within past 3 month document history clinically severe autoimmune disease , syndrome require systemic steroid immunosuppressive agent . Note : Subjects vitiligo resolve childhood asthma/atopy exception rule . Subjects require intermittent use bronchodilator local steroid injection exclude study . Subjects hypothyroidism stable hormone replacement Sjorgen 's syndrome exclude study . 14 . Subject evidence interstitial lung disease active , noninfectious pneumonitis . 15 . Subject active infection require systemic therapy , include active tuberculosis 16 . Subject history current evidence condition , therapy , laboratory abnormality might confound result trial , interfere subject 's participation full duration trial , best interest subject participate , opinion treat investigator . 17 . Subject know psychiatric substance abuse disorder would interfere cooperation requirement trial . 18 . Subject pregnant breastfeeding , expect conceive father child within project duration trial participation ( 2 week prior first dose study treatment , participate study 120 day last dose trial treatment ) . 19 . Subject severe cardiovascular disease , i.e . arrhythmia , require chronic treatment , congestive heart failure ( NYHA Class III IV ) symptomatic ischemic heart disease . 20 . Subject hepatic decompensation ( ChildPugh score &gt; 6 [ class B C ] ) . 21 . Subject uncontrolled thyroid dysfunction 22 . Subject uncontrolled diabetes mellitus 23 . Subject known history Human Immunodeficiency Virus ( HIV ) ( HIV 1/2 antibody ) determine medical record review . 24 . Subject know active Hepatitis B ( e.g. , HBsAg reactive ) Hepatitis C ( e.g. , HCV RNA [ qualitative ] detect ) determine medical record review . 25 . Subject receive live vaccine within 30 day prior first dose trial treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Clinical stage III ( nodal and/or intransit disease ) resectable stage IV melanoma ( MEL ) , without prior treatment</keyword>
</DOC>